

Gender: Male | Birth year: 1950 | WHO: 1

Tumor: Skin - Melanoma | Lesions: CNS, Liver, Lymph Node | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history	8/2020-3/2021 2020 2022 2022 2022 2022 2022	Therapy2 Therapy1 Clinical trial: Trial1 Clinical trial: Trial1 (3 cycles, stop reason: toxicity) Clinical trial (tr2): Trial2 (3 cycles, stop reason: toxicity) Clinical trial: Trial4 (adjuvant, 3 cycles, stop reason: toxicity) Clinical trial: Trial5 (adjuvant and consolidation, 3 cycles, stop reason: toxicity)
Relevant other oncological history	2022 ?	Clinical trial (details unknown)
Previous primary tumor	Lung adenocarcinoma (diagnosed 10/2020, considered non-active)	
Relevant non-oncological history	Pancreatitis	

Recent molecular results

WHOLE_GENOME of ACTN01029999 (01-Oct-2023)

Biopsy location	Liver (purity 98%)
Molecular tissue of origin prediction	Melanoma (100%)
Tumor mutational load / burden	TML high (185) / TMB high (13.7)
Microsatellite (in)stability	Stable
HR status	Proficient
Genes with high driver mutation	BRAF
Amplified genes	MYC
Deleted genes	PTEN
Homozygously disrupted genes	PTEN
Gene fusions	EML4 - ALK fusion
Virus detection	HPV (3 integrations detected)
Potentially actionable events with medium/low driver:	PTEN disruption
IHC results	V600e positive (Panel NGS): BRAF

Approved treatments considered eligible

Treatment
Not yet determined

EMC trials that are open and considered eligible and currently have slots available (1)

Trial	Cohort	Molecular	Warnings
Test Trial 1 TEST-1	Cohort B	None	Undetermined SOC exhaustion

EMC trials that are open and considered eligible but currently have no slots available (2)

Trial	Cohort	Molecular	Warnings
Test Trial 1 TEST-1	Cohort A	BRAF V600E	Undetermined SOC exhaustion

The table continues on the next page

Continued from the previous page

Trial	Cohort	Molecular	Warnings
Test Trial 2 TEST-2	Cohort A	BRAF V600E	None

trial kb trials potentially eligible based on molecular results (8)

Event	Trials
EML4 - ALK fusion	external trial
HPV positive	external trial
MYC amp	external trial
PTEN del	Trial 1
PTEN disruption	external trial
PTEN hom disruption	external trial
TMB High	external trial
TML High	external trial

Molecular Details

IHC results

V600e positive (Panel NGS): BRAF

WHOLE_GENOME (ACTN01029999T, 01-Oct-2023)

General

Purity	Sufficient Quality	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
98%	Yes	High (185)	High (13.7)	Stable	Proficient	*1 HOM (Normal function)	*1 HET (Normal function), *28 HET (Reduced function)

Predicted tumor origin

1. Melanoma	
Combined prediction score	100%
This score is calculated by combining information on:	
(1) SNV types	98%
(2) SNV genomic localisation distribution	99%
(3) Driver genes and passenger characteristics	97%

Other cohorts have a combined prediction of 0% or lower

Drivers

Type	Driver	Driver likelihood	Trials in EMC	Trials in trial kb	Best evidence in kb	Resistance in kb
Mutation (Hotspot)	BRAF V600E (4/6 copies)	High	TEST-1, TEST-2		Approved	
Amplification	MYC amp, 38 copies	High		external trial	Approved	Known resistance
Loss	PTEN del, 0 copies	High		Trial 1		
Known fusion	EML4 - ALK fusion, exon 6 - exon 20	High		external trial	Approved	Known resistance
Disruption (homozygous)	PTEN	High		external trial	Approved	Known resistance
Virus	HPV positive, 3 integrations detected	High		external trial	Approved	Known resistance
Disruption	PTEN, DEL (1.1 discr. / 1.8 undiscr. copies)	Low		external trial	Approved	Known resistance

Clinical Details

Clinical summary

Relevant systemic treatment history	8/2020-3/2021	Therapy2
	2020	Therapy1
	2022	Clinical trial: Trial1
	2022	Clinical trial: Trial1 (3 cycles, stop reason: toxicity)
	2022	Clinical trial (tr2): Trial2 (3 cycles, stop reason: toxicity)
	2022	Clinical trial: Trial4 (adjuvant, 3 cycles, stop reason: toxicity)
	2022	Clinical trial: Trial5 (adjuvant and consolidation, 3 cycles, stop reason: toxicity)
Relevant other oncological history	2022	Clinical trial (details unknown)
	?	
Previous primary tumor	Lung adenocarcinoma (diagnosed 10/2020, considered non-active)	
Relevant non-oncological history	Pancreatitis	

Patient current details (26-Sep-2023)

Unresolved toxicities grade => 2	Fatigue (2)
Cancer-related complications	Ascites
Known allergies	Wasps (Environment)
Recent surgeries	06-Sep-2023

Tumor details (26-Sep-2023)

Measurable disease	Yes
CNS lesion status	Present CNS lesions (active)
Brain lesion status	No known brain lesions

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
Ibuprofen		06-Sep-2023	21-Oct-2023	750 - 1000 mg	1 / day
Prednison		06-Sep-2023	21-Oct-2023	750 - 1000 mg	1 / 3 months

Blood transfusions

Product	Date
Thrombocyte concentrate	21-Sep-2023

Trial Matching Summary

EMC trials and cohorts that meet molecular requirements and may be eligible, but are closed (0)

None

EMC trials and cohorts that are open but considered ineligible (1)

Trial	Cohort	Molecular	Ineligibility reasons
Test Trial 2 TEST-2	Cohort B		Vemurafenib treatment